ADRB2 and cancer: In summary, these findings demonstrate for the first time that ADRB-2 antagonists could be used as promising therapeutic agents to treat RCCs, acting through inhibition of cancer cell proliferation, tumor angiogenesis, and inflammation (Figure 7).